Centre for Population Health, Burnet Institute, Melbourne, VIC, Australia.
Med J Aust. 2011 Mar 7;194(5):249-52. doi: 10.5694/j.1326-5377.2011.tb02957.x.
To describe the proportion of 16-29-year-olds tested for chlamydia by Australian general practitioners in a 12-month period.
Between October 2007 and September 2008, the national chlamydia testing rate in 16-29-year-olds was calculated by dividing the number of Medicare-reimbursed chlamydia tests by two denominators: (i) Medicare-reimbursed GP consultations; and (ii) estimated resident populations adjusted for the proportion who were sexually active.
GP chlamydia testing rates in 16-29-year-olds per 100 patients attending a GP consultation and per 100 sexually active population, by patient age and sex, state/territory of residence, and remoteness area.
Among the estimated Australian population of 16-29-year-olds, 85.6% of females and 64.4% of males had at least one GP consultation in the 12-month period. The national GP chlamydia testing rate per 100 patients was 8.9% (95% CI, 8.88%-8.94%). The national GP chlamydia testing rate per 100 sexually active population was 8.0% (95% CI, 7.92%-7.98%). The rate per 100 sexually active population was higher in females (12.5%) compared with males (3.7%) (P < 0.01); higher in 20-24-year-olds (9.0%) compared with 16-19-year-olds (8.7%) and 25-29-year-olds (6.6%) (P < 0.01); higher in those living in non-metropolitan areas (11.0%) compared with metropolitan areas (8.4%) (P < 0.01); and highest in those living in the Northern Territory (21.4%) compared with other jurisdictions (P < 0.01).
Despite clinical guidelines recommending annual chlamydia testing for sexually active 15-29-year-olds, our analysis showed that a high proportion of young people aged 16-29 years attend a GP each year, but few of the sexually active population in this age group were tested for chlamydia in general practice. Strategies are needed to support GPs to enhance chlamydia testing in young people.
描述在 12 个月内澳大利亚全科医生为衣原体检测的 16-29 岁人群比例。
在 2007 年 10 月至 2008 年 9 月期间，通过将医疗保险报销的衣原体检测数量除以两个分母来计算 16-29 岁人群的全国衣原体检测率：（i）医疗保险报销的全科医生咨询量；（ii）调整为活跃人口比例的估计居民人数。
按患者年龄和性别、居住州/领地、偏远地区以及按每 100 名接受全科医生咨询的患者和每 100 名活跃人口计算的 16-29 岁人群的全科医生衣原体检测率。
在估计的澳大利亚 16-29 岁人群中，85.6%的女性和 64.4%的男性在 12 个月内至少有一次全科医生咨询。全国每 100 名患者的全科医生衣原体检测率为 8.9%（95%CI，8.88%-8.94%）。全国每 100 名活跃人口的全科医生衣原体检测率为 8.0%（95%CI，7.92%-7.98%）。每 100 名活跃人口的检测率在女性中较高（12.5%），而在男性中较低（3.7%）（P<0.01）；在 20-24 岁人群中较高（9.0%），而在 16-19 岁人群和 25-29 岁人群中较低（8.7%和 6.6%）（P<0.01）；在非大都市地区（11.0%）较高，而在大都市地区（8.4%）较低（P<0.01）；在北领地（21.4%）最高，而在其他司法管辖区（P<0.01）。
尽管临床指南建议每年对 15-29 岁有性行为的活跃人群进行衣原体检测，但我们的分析表明，在每年有相当比例的 16-29 岁年轻人看全科医生，但在该年龄段的有性行为人群中，很少有人在全科医生诊所接受衣原体检测。需要采取策略来支持全科医生增加年轻人的衣原体检测。
